Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?
Open Access
- 18 June 2020
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (2), 222-229
- https://doi.org/10.14218/jcth.2020.00026
Abstract
The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden; yet, there is still a lack of approved methods to prevent or reverse liver fibrosis. Therefore, effective hepatic antifibrotic drugs are urgently needed. The activation and proliferation of hepatic stellate cells are still the mechanisms of fibrosis that remain the focus of therapeutic research. In recent years, significant progress has been made in the development and applicability of antifibrosis drugs. In this review, we summarize the effectiveness and safety of available antifibrosis drugs utilizing different targets. In addition, some characteristics of antifibrosis drugs in phase II and III trials are introduced in detail.Keywords
This publication has 75 references indexed in Scilit:
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Antifibrotic Effects of a Recombinant Adeno-Associated Virus Carrying Small Interfering RNA Targeting TIMP-1 in Rat Liver FibrosisThe American Journal of Pathology, 2013
- Autophagy Releases Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human TissuesGastroenterology, 2012
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosisJournal of Hepatology, 2012
- Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in miceJournal of Hepatology, 2011
- Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosisJournal of Hepatology, 2011
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis CGastroenterology, 2008
- Senescence of Activated Stellate Cells Limits Liver FibrosisCell, 2008
- NF-κB is a critical regulator of the survival of rodent and human hepatic myofibroblastsJournal of Hepatology, 2008